Home | Business News | Browse by Publication | B | Biotech Business

METABASIS GETS GOOD RESULTS FROM MB07803 PHASE 2A TRIAL.

Publication: Biotech Business
Publication Date: 01-JUN-08 		Format: Online
Delivery: Immediate Online Access

Article Excerpt
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) San Diego, Calif. has announced that MB07803 met its primary efficacy endpoint with results demonstrating a statistically and clinically significant reduction in fasting plasma glucose (FPG) at day 28 in its Phase 2a clinical trial. The study also showed that MB07803 was safe and well tolerated. MB07803 is Metabasis' product candidate for the treatment of type 2 diabetes that acts by inhibiting fructose-1,6-bisphosphatase (FBPase).

This 28-day proof-of-concept clinical trial was a randomized, double-blind, placebo-controlled trial involving 105 patients with type 2 diabetes with a mean baseline fasting plasma glucose of 187 mg/dL and mean baseline HbA1c of 8.2%. Patients received either placebo or MB07803 at an oral dose of 10, 50, 100 or 200 mg once daily. The primary efficacy endpoint of the...

Access Full Article, Compliments of Goliath

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.